Kai Wirt@Aktien2022

2Année

I would still keep Novavax and possibly wait that the vlt bring out new vaccines, which can increase sales. I am also in the red with them...🥴

Afficher l'original (Allemand)

J'aime••Réponse

Leuchtturm@Leuchtturm

2Année

@Aktien2022 what does the company's information say about the development of new vaccines, so long the company is not to be seen as "growth potential"

Afficher l'original (Allemand)

J'aime••Réponse

Leuchtturm@Leuchtturm

2Année

@Aktien2022 because research is one thing - clinical trials and market approvals are another 🤔.

Afficher l'original (Allemand)

J'aime••Réponse